ZA200106075B - Phenylalaninol derivatives. - Google Patents
Phenylalaninol derivatives. Download PDFInfo
- Publication number
- ZA200106075B ZA200106075B ZA200106075A ZA200106075A ZA200106075B ZA 200106075 B ZA200106075 B ZA 200106075B ZA 200106075 A ZA200106075 A ZA 200106075A ZA 200106075 A ZA200106075 A ZA 200106075A ZA 200106075 B ZA200106075 B ZA 200106075B
- Authority
- ZA
- South Africa
- Prior art keywords
- lower alkyl
- compound
- carbonyl
- group
- alkyl
- Prior art date
Links
- STVVMTBJNDTZBF-VIFPVBQESA-N L-phenylalaninol Chemical class OC[C@@H](N)CC1=CC=CC=C1 STVVMTBJNDTZBF-VIFPVBQESA-N 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- 150000001875 compounds Chemical class 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 125000001589 carboacyl group Chemical group 0.000 claims description 36
- -1 cyano, hydroxy Chemical group 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 33
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 125000004414 alkyl thio group Chemical group 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 21
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 21
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000003435 aroyl group Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 10
- 229960005190 phenylalanine Drugs 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 238000011321 prophylaxis Methods 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-Phenylalanine Natural products OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 13
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 6
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- LFMFPKKYRXFHHZ-UHFFFAOYSA-N R24 Chemical compound C1=C(Cl)C(C)=CC=C1NC1=NC(N)=C(C=CC=C2)C2=N1 LFMFPKKYRXFHHZ-UHFFFAOYSA-N 0.000 description 1
- 241000288960 Saguinus oedipus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical compound C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12049899P | 1999-02-18 | 1999-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200106075B true ZA200106075B (en) | 2002-10-24 |
Family
ID=22390691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200106075A ZA200106075B (en) | 1999-02-18 | 2001-07-24 | Phenylalaninol derivatives. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6420600B1 (fr) |
| EP (1) | EP1154987B1 (fr) |
| JP (1) | JP2002537283A (fr) |
| KR (1) | KR100636458B1 (fr) |
| CN (1) | CN1213020C (fr) |
| AT (1) | ATE264835T1 (fr) |
| AU (1) | AU771938B2 (fr) |
| BR (1) | BR0008368A (fr) |
| CA (1) | CA2362833C (fr) |
| CZ (1) | CZ20012984A3 (fr) |
| DE (1) | DE60010049T2 (fr) |
| DK (1) | DK1154987T3 (fr) |
| ES (1) | ES2218116T3 (fr) |
| HK (1) | HK1043589A1 (fr) |
| HR (1) | HRP20010594B1 (fr) |
| HU (1) | HUP0200343A3 (fr) |
| ID (1) | ID30057A (fr) |
| IL (2) | IL144641A0 (fr) |
| MA (1) | MA26772A1 (fr) |
| MX (1) | MXPA01008178A (fr) |
| NO (1) | NO20013946L (fr) |
| PL (1) | PL349463A1 (fr) |
| PT (1) | PT1154987E (fr) |
| RU (1) | RU2238265C2 (fr) |
| SI (1) | SI1154987T1 (fr) |
| TR (1) | TR200102395T2 (fr) |
| WO (1) | WO2000048988A1 (fr) |
| YU (1) | YU58601A (fr) |
| ZA (1) | ZA200106075B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6939855B2 (en) * | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
| EP1741428A3 (fr) * | 1999-08-13 | 2007-05-09 | Biogen Idec MA, Inc. | inhibiteurs d'adhésion cellulaire |
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| CA2525934A1 (fr) | 2003-05-20 | 2004-12-02 | Genentech, Inc. | Inhibiteurs de type thiocarbamates d'integrines alpha-4 |
| WO2006081986A1 (fr) * | 2005-02-07 | 2006-08-10 | F.Hoffmann-La Roche Ag | Combinaison de bambuterol et d'inhibiteur d'integrine |
| WO2006094640A2 (fr) * | 2005-03-04 | 2006-09-14 | F.Hoffmann-La Roche Ag | Association de roflumilast et d'un inhibiteur de l'integrine, et procede de traitement |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE584914A (fr) | 1958-11-24 | |||
| US3527793A (en) | 1967-08-18 | 1970-09-08 | Bristol Myers Co | Phenylglycine derivatives |
| IT1190378B (it) | 1985-06-21 | 1988-02-16 | Isf Spa | Derivati pirrolidonici |
| US5039805A (en) | 1988-12-08 | 1991-08-13 | Hoffmann-La Roche Inc. | Novel benzoic and phenylacetic acid derivatives |
| US5463116A (en) | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| CN1046725C (zh) | 1994-06-20 | 1999-11-24 | 武田药品工业株式会社 | 稠合的咪唑化合物,它们的制备和应用 |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| US5804595A (en) | 1995-12-05 | 1998-09-08 | Regents Of The University Of Minnesota | Kappa opioid receptor agonists |
| ATE212978T1 (de) * | 1996-03-29 | 2002-02-15 | Searle & Co | Para-substituierte phenylpropansäure derivate als integrin-antagonisten |
| PT889877E (pt) | 1996-03-29 | 2002-02-28 | Searle & Co | Derivados fenileno meta substituidos e sua utilizacao como antagonitas ou inibidores integrina alfa v beta3 |
| ID19155A (id) * | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| CA2291778A1 (fr) * | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire |
| CA2301377C (fr) * | 1997-08-22 | 2009-10-06 | F. Hoffmann-La Roche Ag | Derives de n-alcanoylphenilalanine |
| BR9811988A (pt) * | 1997-08-22 | 2000-09-05 | Hoffmann La Roche | Derivados de n-alcanoilfenilalanina |
| ATE273273T1 (de) | 1998-02-26 | 2004-08-15 | Celltech Therapeutics Ltd | Phenylalaninderivate als inhibitoren von alpha4 integrinen |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
-
2000
- 2000-02-12 RU RU2001124601A patent/RU2238265C2/ru not_active IP Right Cessation
- 2000-02-12 BR BR0008368-2A patent/BR0008368A/pt not_active Application Discontinuation
- 2000-02-12 ES ES00903692T patent/ES2218116T3/es not_active Expired - Lifetime
- 2000-02-12 WO PCT/EP2000/001168 patent/WO2000048988A1/fr active IP Right Grant
- 2000-02-12 TR TR2001/02395T patent/TR200102395T2/xx unknown
- 2000-02-12 ID IDW00200101769A patent/ID30057A/id unknown
- 2000-02-12 SI SI200030405T patent/SI1154987T1/xx unknown
- 2000-02-12 DK DK00903692T patent/DK1154987T3/da active
- 2000-02-12 DE DE60010049T patent/DE60010049T2/de not_active Expired - Lifetime
- 2000-02-12 KR KR1020017010537A patent/KR100636458B1/ko not_active IP Right Cessation
- 2000-02-12 HU HU0200343A patent/HUP0200343A3/hu unknown
- 2000-02-12 MX MXPA01008178A patent/MXPA01008178A/es active IP Right Grant
- 2000-02-12 CA CA002362833A patent/CA2362833C/fr not_active Expired - Fee Related
- 2000-02-12 PL PL00349463A patent/PL349463A1/xx not_active Application Discontinuation
- 2000-02-12 EP EP00903692A patent/EP1154987B1/fr not_active Expired - Lifetime
- 2000-02-12 AU AU25486/00A patent/AU771938B2/en not_active Ceased
- 2000-02-12 CZ CZ20012984A patent/CZ20012984A3/cs unknown
- 2000-02-12 IL IL14464100A patent/IL144641A0/xx active IP Right Grant
- 2000-02-12 PT PT00903692T patent/PT1154987E/pt unknown
- 2000-02-12 JP JP2000599729A patent/JP2002537283A/ja active Pending
- 2000-02-12 YU YU58601A patent/YU58601A/sh unknown
- 2000-02-12 AT AT00903692T patent/ATE264835T1/de not_active IP Right Cessation
- 2000-02-12 CN CNB008038694A patent/CN1213020C/zh not_active Expired - Fee Related
- 2000-02-17 US US09/506,062 patent/US6420600B1/en not_active Expired - Fee Related
-
2001
- 2001-07-24 ZA ZA200106075A patent/ZA200106075B/en unknown
- 2001-07-30 IL IL144641A patent/IL144641A/en not_active IP Right Cessation
- 2001-08-10 HR HR20010594A patent/HRP20010594B1/xx not_active IP Right Cessation
- 2001-08-14 NO NO20013946A patent/NO20013946L/no not_active Application Discontinuation
- 2001-08-17 MA MA26298A patent/MA26772A1/fr unknown
-
2002
- 2002-07-22 HK HK02105393A patent/HK1043589A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1154993B1 (fr) | Derives thioamides | |
| ZA200203533B (en) | 4-pyrimidinyl-N-acyl-L-phenylalanines. | |
| KR101245062B1 (ko) | 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법 | |
| ZA200106075B (en) | Phenylalaninol derivatives. | |
| RU2001124596A (ru) | Тиоамидные производные | |
| CA2329930A1 (fr) | Composes exercant une activite d'inhibition reversible de carnitine palmityl-transferase | |
| JP2004504388A5 (fr) | ||
| SI9520084A (en) | Use of heterocyclic compounds as dopamines-d3 ligands | |
| EP1244625A1 (fr) | 4-pyridinyl-n-acyl-l-phenylalanines | |
| PT100158A (pt) | Uso de antagonistas da angiotensina ii para a producao de um medicamento para otratamento de psoriase | |
| UA113053C2 (xx) | Гетероциклічні сполуки, придатні для лікування дисліпідемії | |
| US4923885A (en) | 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents | |
| JPH0748360A (ja) | ビフェニルテトラゾール誘導体 | |
| EP0563153B1 (fr) | N-(mercaptoalkyle)amides | |
| AU2003210811A1 (en) | Arylsulfonamidobenzylic compounds | |
| EP1476423A2 (fr) | Composes arylsulfonamidobenzyliques | |
| WO2005016277A2 (fr) | Composes arylsulfonamidobenzyliques | |
| JP2019504051A (ja) | インドリジン誘導体、組成物、及び使用方法 | |
| CA2468302A1 (fr) | Composes servant au traitement d'une inflammation, des diabetes et des troubles associes | |
| US5219886A (en) | Mercapto-acylamino acids | |
| US5347011A (en) | Substituted triazoles as angiotensin II inhibitors | |
| KR100658962B1 (ko) | 스피로이미다졸리딘 유도체, 이의 제조방법 및 이를 포함하는 약제학적 제제 | |
| AU747977B2 (en) | Cytostatic agents | |
| RU2187499C2 (ru) | Цитостатические агенты | |
| TH9788B (th) | กรดฟลูออริเนเทดไฮดรอกซีแอลคิลควินโนลีนในฐานะเป็นสารต่อต้านลูโคไตรอีน |